469 related articles for article (PubMed ID: 29500030)
1. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial.
Scheltema NM; Nibbelke EE; Pouw J; Blanken MO; Rovers MM; Naaktgeboren CA; Mazur NI; Wildenbeest JG; van der Ent CK; Bont LJ
Lancet Respir Med; 2018 Apr; 6(4):257-264. PubMed ID: 29500030
[TBL] [Abstract][Full Text] [Related]
2. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.
Man WH; Scheltema NM; Clerc M; van Houten MA; Nibbelke EE; Achten NB; Arp K; Sanders EAM; Bont LJ; Bogaert D
Lancet Respir Med; 2020 Oct; 8(10):1022-1031. PubMed ID: 32203712
[TBL] [Abstract][Full Text] [Related]
3. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants.
Blanken MO; Rovers MM; Molenaar JM; Winkler-Seinstra PL; Meijer A; Kimpen JL; Bont L;
N Engl J Med; 2013 May; 368(19):1791-9. PubMed ID: 23656644
[TBL] [Abstract][Full Text] [Related]
4. Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks.
Blanken M; Rovers M; Sanders E; Bont L
Contemp Clin Trials; 2012 Nov; 33(6):1287-92. PubMed ID: 22820319
[TBL] [Abstract][Full Text] [Related]
5. Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. Six-Year Follow-up Study.
Mochizuki H; Kusuda S; Okada K; Yoshihara S; Furuya H; Simões EAF;
Am J Respir Crit Care Med; 2017 Jul; 196(1):29-38. PubMed ID: 28152315
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.
O'Brien KL; Chandran A; Weatherholtz R; Jafri HS; Griffin MP; Bellamy T; Millar EV; Jensen KM; Harris BS; Reid R; Moulton LH; Losonsky GA; Karron RA; Santosham M;
Lancet Infect Dis; 2015 Dec; 15(12):1398-408. PubMed ID: 26511956
[TBL] [Abstract][Full Text] [Related]
7. RSV hospitalization in infancy increases the risk of current wheeze at age 6 in late preterm born children without atopic predisposition.
Korsten K; Blanken MO; Buiteman BJM; Nibbelke EE; Naaktgeboren CA; Bont LJ; Wildenbeest JG
Eur J Pediatr; 2019 Apr; 178(4):455-462. PubMed ID: 30637465
[TBL] [Abstract][Full Text] [Related]
8. Palivizumab prophylaxis, respiratory syncytial virus and subsequent development of asthma.
Igde M; Kabasakal H; Ozturk O; Karatekin G; Aygun C
Minerva Pediatr; 2018 Jun; 70(3):252-259. PubMed ID: 29795072
[TBL] [Abstract][Full Text] [Related]
9. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
10. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants.
Yoshihara S; Kusuda S; Mochizuki H; Okada K; Nishima S; Simões EA;
Pediatrics; 2013 Nov; 132(5):811-8. PubMed ID: 24127479
[TBL] [Abstract][Full Text] [Related]
11. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.
Cetinkaya M; Oral TK; Karatekin S; Cebeci B; Babayigit A; Yesil Y
Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1629-1634. PubMed ID: 28391538
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
Hashmi NA; Cosgrove JF; MacMahon P
Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
[TBL] [Abstract][Full Text] [Related]
14. Palivizumab prophylaxis in preterm infants and subsequent wheezing/asthma: 10-year follow-up study.
Kato M; Mochizuki H; Kama Y; Kusuda S; Okada K; Yoshihara S; Furuya H; Simões EAF;
Pediatr Pulmonol; 2024 Mar; 59(3):743-749. PubMed ID: 38116923
[TBL] [Abstract][Full Text] [Related]
15. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
Simões EAF; Madhi SA; Muller WJ; Atanasova V; Bosheva M; Cabañas F; Baca Cots M; Domachowske JB; Garcia-Garcia ML; Grantina I; Nguyen KA; Zar HJ; Berglind A; Cummings C; Griffin MP; Takas T; Yuan Y; Wählby Hamrén U; Leach A; Villafana T
Lancet Child Adolesc Health; 2023 Mar; 7(3):180-189. PubMed ID: 36634694
[TBL] [Abstract][Full Text] [Related]
17. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
Simoes EA; Groothuis JR; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick LM; Kimpen JL;
J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
[TBL] [Abstract][Full Text] [Related]
18. Respiratory syncytial virus immunoprophylaxis in high-risk infants and development of childhood asthma.
Carroll KN; Gebretsadik T; Escobar GJ; Wu P; Li SX; Walsh EM; Mitchel E; Sloan CD; Dupont WD; Hartert TV
J Allergy Clin Immunol; 2017 Jan; 139(1):66-71.e3. PubMed ID: 27212083
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of palivizumab immunoprophylaxis in infants with respiratory syncytial virus disease in Colombia.
Piñeros JG; De la Hoz-Valle J; Galvis C; Celis A; Ovalle O; Sandoval CC; Orrego J; Vides S; Rojas I; Bustamante H; Gallón C; Mesa JA
J Infect Dev Ctries; 2021 Nov; 15(11):1708-1713. PubMed ID: 34898500
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
